MAPT and neurodegenerative disease: This biomarker lacks the ability to specifically distinguish AD since the amount of T-tau is elevated in a wide range of neurodegenerative diseases (Ariaei and Ramezani, 2023, Hesse et al., 2001, Zetterberg et al., 2006).